LRMR — Larimar Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374690 ·
Last close
$2.99
Market Cap
$310.61M
52W High
$6.42
52W Low
$1.91
ADV30
1,550,006
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -32,464,000 | -31,135,000 | 140,504,000 | 76,986,000 | 39,038,000 |
| Jun 2026 | 0 | — | -34,351,000 | -32,782,000 | 165,302,000 | 92,687,000 | 37,920,000 |
| Mar 2026 | 0 | — | -31,117,000 | -29,613,000 | 208,511,000 | 177,913,000 | 50,478,000 |
| Dec 2025 | 0 | — | -64,018,000 | -62,498,000 | 145,842,000 | 85,412,000 | 67,757,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-155,924,000
Investing CF
$55,108,000
Financing CF
$172,766,000
CapEx
$-91,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.95
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-497,226,000
Inventory
—
Receivables
$267,000
ST Investments
$63,580,000
EBIT TTM
$-178,985,000
Pretax Income TTM
$-172,605,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,497,000 | -165,673,000 | 145,842,000 | 67,757,000 | 78,085,000 | -113,201,000 |
| Dec 2024 | 0 | -90,890,000 | -80,604,000 | 200,225,000 | 28,413,000 | 171,812,000 | -70,760,000 |
| Dec 2023 | 0 | -41,758,000 | -36,949,000 | 95,935,000 | 14,215,000 | 81,720,000 | -33,459,000 |
| Dec 2022 | 0 | -36,526,000 | -35,355,000 | 126,405,000 | 15,502,000 | 110,903,000 | -27,569,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-172,605,000
OpCashFlow TTM
—
Assets (Latest)
$165,302,000
Forward EPS
$-1.06
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $3.23 · call oi: 1,226 · put oi: 83
Expected Move to 2027-01-15:
±$1.48
(45.89%) —
implied range
$1.75 –
$4.71
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INO | INOVIO PHARMACEUTICALS, INC. | $305.31M | $1.63 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $318.00M | $3.96 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $321.15M | $3.01 | — |
| ALT | Altimmune, Inc. | $297.72M | $1.53 | — |
| GALT | GALECTIN THERAPEUTICS INC | $293.47M | $2.91 | — |
News headlines (Yahoo Finance, 1h cache)
Larimar: Q3 Earnings Snapshot
2026-11-16 12:23 · Yahoo
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
2026-11-16 12:15 · Yahoo
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
2026-11-09 21:05 · Yahoo
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
2026-11-05 21:05 · Yahoo
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-04 21:05 · Yahoo
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-10-05 12:35 · Yahoo
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
2026-09-29 20:05 · Yahoo
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
2026-07-15 15:43 · Yahoo
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
2026-07-08 22:44 · Yahoo
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
2026-07-03 13:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.